SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report) was down 20% during mid-day trading on Tuesday . The stock traded as low as C$4.65 and last traded at C$4.65. Approximately 1,827 shares were traded during trading, a decline of 23% from the average daily volume of 2,364 shares. The stock had previously closed at C$5.81.
SanBio Stock Down 20.0 %
The business’s 50 day moving average is C$4.37 and its 200-day moving average is C$4.03.
SanBio Company Profile
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
Read More
- Five stocks we like better than SanBio
- How to Use the MarketBeat Stock Screener
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- 3 Warren Buffett Stocks to Buy Now
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- What is Insider Trading? What You Can Learn from Insider Trading
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.
